Optimizing the use of vilobelimab for the treatment of COVID-19

References

• McCarthy MW. Treatment of severe COVID-19: an evolving paradigm. Expert Opinion On Pharmacotherapy. 2022;23(17):1–5. doi: 10.1080/14656566.2022.2140041
   PubMed Web of Science ®Google Scholar
• Horby P, Lim WS, Emberson JR, et al. Dexamethasone in hospitalized patients with Covid-19. N Engl J Med. 2021;384(8):693–704.
   PubMed Web of Science ®Google Scholar
• Focosi D, Maggi F, McConnell S, et al. Very low levels of remdesivir resistance in SARS-COV-2 genomes after 18 months of massive usage during the COVID-19 pandemic: A GISAID exploratory analysis. Antiviral Research. 2022;198:105247.
   PubMed Web of Science ®Google Scholar
• McCarthy MW. Current and emerging immunomodulators for treatment of SARS-CoV2 infection (COVID-19). Expert Opinion On Pharmacotherapy. 2022;23(5):623–628. doi: 10.1080/14656566.2022.2035360
   PubMed Web of Science ®Google Scholar
• Basu D, Chavda VP, Mehta AA. Therapeutics for COVID-19 and post COVID-19 complications: An update. Curr Res Pharmacol Drug Discov. 2022;3:100086. doi: 10.1016/j.crphar.2022.100086
   PubMedGoogle Scholar
• Chavda VP, Prajapati R, Lathigara D, et al. Therapeutic monoclonal antibodies for COVID-19 management: an update. Expert Opinion On Biological Therapy. 2022;22(6):763–780. doi: 10.1080/14712598.2022.2078160
   PubMed Web of Science ®Google Scholar
• Hwang YC, Lu RM, Su SC, et al. Monoclonal antibodies for COVID-19 therapy and SARS-CoV-2 detection. J Biomed Sci. 2022;29(1):1. doi: 10.1186/s12929-021-00784-w
   PubMed Web of Science ®Google Scholar
• Taylor PC, Adams AC, Hufford MM, et al. Neutralizing monoclonal antibodies for treatment of COVID-19. Nat Rev Immunol. 2021;21(6):382–393. doi: 10.1038/s41577-021-00542-x
   PubMed Web of Science ®Google Scholar
• Sadeghi A, Sadeghi S, Peikar MS, et al. Efficacy of plasmapheresis in neutropenic patients suffering from cytokine storm because of severe COVID-19 infection. Blood Res. 2023;58(2):91–98. doi: 10.5045/br.2023.2022201
   PubMed Web of Science ®Google Scholar
• Koh JY, Ko JH, Lim SY, et al. Triple immune modulator therapy for aberrant hyperinflammatory responses in severe COVID-19. Clinical Immunology. 2023;251:109628.
   PubMed Web of Science ®Google Scholar
• Bermejo-Martin JF, García-Mateo N, Motos A, et al. Effect of viral storm in patients admitted to intensive care units with severe COVID-19 in Spain: a multicentre, prospective, cohort study. The Lancet Microbe. 2023;4(6):e431–e441. doi: 10.1016/S2666-5247(23)00041-1
   PubMedGoogle Scholar
• Passi R, Brittan M, Baker AH. The role of the endothelium in severe acute respiratory syndrome coronavirus 2 infection and pathogenesis. Current Opinion In Physiology. 2023;34:100670. doi: 10.1016/j.cophys.2023.100670
   PubMed Web of Science ®Google Scholar
• Barrett TJ, Cornwell M, Myndzar K, et al. Platelets amplify endotheliopathy in COVID-19. Sci Adv. 2021;7(37):eabh2434. doi: 10.1126/sciadv.abh2434
   PubMed Web of Science ®Google Scholar
• Vassiliou AG, Vrettou CS, Keskinidou C, et al. Endotheliopathy in Acute COVID-19 and Long COVID. Int J Mol Sci. 2023;24(9). doi: 10.3390/ijms24098237
   Web of Science ®Google Scholar
• Kumar A, Prasoon P, Sekhawat PS, et al. Pathogenesis guided therapeutic management of COVID-19: an immunological perspective. International Reviews Of Immunology. 2021;40(1–2):54–71. doi: 10.1080/08830185.2020.1840566
   PubMed Web of Science ®Google Scholar
• Gao T, Zhu L, Liu H, et al. Highly pathogenic coronavirus N protein aggravates inflammation by MASP-2-mediated lectin complement pathway overactivation. Sig Transduct Target Ther. 2022;7(1):318. doi: 10.1038/s41392-022-01133-5
   PubMed Web of Science ®Google Scholar
• Zelek WM, Harrison RA. Complement and COVID-19: Three years on, what we know, what we don’t know, and what we ought to know. Immunobiology. 2023;228(3):152393. doi: 10.1016/j.imbio.2023.152393
   PubMed Web of Science ®Google Scholar
• Czermak BJ, Lentsch AB, Bless NM, et al. Role of complement in in vitro and in vivo lung inflammatory reactions. Journal Of Leukocyte Biology. 1998;64(1):40–48. doi: 10.1002/jlb.64.1.40
   PubMed Web of Science ®Google Scholar
• Zhang H, Gerasimovskaya E, McCarthy MK, et al. Local complement contributes to pathogenic activation of lung endothelial cells in SARS-CoV-2 infection. Am J Respir Cell Mol Biol. 2023. doi:10.1165/rcmb.2022-0373OC.
   Web of Science ®Google Scholar
• Hurler L, Szilágyi Á, Mescia F, et al. Complement lectin pathway activation is associated with COVID-19 disease severity, independent of. Front Immunol. 2023;14:1162171.
   PubMed Web of Science ®Google Scholar
• Afzali B, Noris M, Lambrecht BN, et al. The state of complement in COVID-19. Nat Rev Immunol. 2022;22(2):77–84. doi: 10.1038/s41577-021-00665-1
   PubMed Web of Science ®Google Scholar
• Pires BG, Calado RT. Hyper-inflammation and complement in COVID-19. Am J Hematol. 2023;98(Suppl 4):S74–S81. doi: 10.1002/ajh.26746
   PubMedGoogle Scholar
• Vlaar APJ, Lim EHT, de Bruin S, et al. The anti-C5a antibody vilobelimab efficiently inhibits C5a in patients with severe COVID-19. Clin Transl Sci. 2022;15(4):854–858. doi: 10.1111/cts.13213
   PubMed Web of Science ®Google Scholar
• Sun S, Zhao G, Liu C, et al. Treatment with anti-C5a antibody improves the outcome of H7N9 virus infection in African green monkeys. Clinical Infectious Diseases. 2015;60(4):586–595. doi: 10.1093/cid/ciu887
   PubMed Web of Science ®Google Scholar
• Nakae H, Endo S, Inada K, et al. Chronological changes in the complement system in sepsis. Surg Today. 1996;26(4):225–229. doi: 10.1007/BF00311579.
   PubMed Web of Science ®Google Scholar
• Czermak BJ, Sarma V, Pierson CL, et al. Protective effects of C5a blockade in sepsis. Nat Med. 1999;5(7):788–792. doi: 10.1038/10512
   PubMed Web of Science ®Google Scholar
• Hoehlig K, Maasch C, Shushakova N, et al. A novel C5a-neutralizing mirror-image (l-)aptamer prevents organ failure and improves survival in experimental sepsis. Molecular Therapy. 2013;21(12):2236–2246. doi: 10.1038/mt.2013.178
   PubMed Web of Science ®Google Scholar
• Rivers EP, Jaehne AK, Nguyen HB, et al. Early biomarker activity in severe sepsis and septic shock and a contemporary review of immunotherapy trials: not a time to give up, but to give it earlier. Shock. 2013;39(2):127–137. doi: 10.1097/SHK.0b013e31827dafa7
   PubMed Web of Science ®Google Scholar
• Carvelli J, Demaria O, Vély F, et al. Association of COVID-19 inflammation with activation of the C5a-C5aR1 axis. Nature. 2020;588(7836):146–150. doi: 10.1038/s41586-020-2600-6
   PubMed Web of Science ®Google Scholar
• Osburn WO, Smith K, Yanek L, et al. Markers of endothelial cell activation are associated with the severity of pulmonary disease in COVID-19. PLoS One. 2022;17(5):e0268296. doi: 10.1371/journal.pone.0268296
   PubMed Web of Science ®Google Scholar
• Boussier J, Yatim N, Marchal A, et al. Severe COVID-19 is associated with hyperactivation of the alternative complement pathway. J Allergy Clin Immunol. 2022;149(2):550–6.e2. doi: 10.1016/j.jaci.2021.11.004
   PubMed Web of Science ®Google Scholar
• Giamarellos-Bourboulis EJ, Argyropoulou M, Kanni T, et al. Clinical efficacy of complement C5a inhibition by IFX-1 in hidradenitis suppurativa: an open-label single-arm trial in patients not eligible for adalimumab. Br J Dermatol. 2020;183(1):176–178. doi: 10.1111/bjd.18877
   PubMed Web of Science ®Google Scholar
• Lu JD, Milakovic M, Ortega-Loayza AG, et al. Pyoderma gangrenosum: proposed pathogenesis and current use of biologics with an emphasis on complement C5a inhibitor IFX-1. Expert Opinion On Investigational Drugs. 2020;29(11):1179–1185. doi: 10.1080/13543784.2020.1819981
   PubMed Web of Science ®Google Scholar
• Bauer M, Weyland A, Marx G, et al. Efficacy and safety of vilobelimab (IFX-1), a novel monoclonal anti-c5a antibody, in patients with early severe sepsis or septic shock-A randomized, placebo-controlled, double-blind, multicenter, phase iia trial (SCIENS study). Crit Care Explor. 2021;3(11):e0577. doi: 10.1097/CCE.0000000000000577
   PubMedGoogle Scholar
• Vlaar APJ, de Bruin S, Busch M, et al. Anti-C5a antibody IFX-1 (vilobelimab) treatment versus best supportive care for patients with severe COVID-19 (PANAMO): an exploratory, open-label, phase 2 randomised controlled trial. Lancet Rheumatol. 2020;2(12):e764–e73. doi: 10.1016/S2665-9913(20)30341-6
   PubMedGoogle Scholar
• Vlaar APJ, Witzenrath M, van Paassen P, et al. Anti-C5a antibody (vilobelimab) therapy for critically ill, invasively mechanically ventilated patients with COVID-19 (PANAMO): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Respir Med. 2022;10(12):1137–1146. doi: 10.1016/S2213-2600(22)00297-1
   PubMed Web of Science ®Google Scholar
• Lim EHT, Vlaar APJ, Bos LDJ, et al. Anti-C5a antibody vilobelimab treatment and the effect on biomarkers of inflammation and coagulation in patients with severe COVID-19: a substudy of the phase 2 PANAMO trial. Respir Res. 2022;23(1):375. doi: 10.1186/s12931-022-02278-1
   PubMed Web of Science ®Google Scholar
• Grant RA, Morales-Nebreda L, Markov NS, et al. Alveolitis in severe SARS-CoV-2 pneumonia is driven by self-sustaining circuits between infected alveolar macrophages and T cells. bioRxiv. 2020. doi:10.1101/2020.08.05.238188.
   Google Scholar
• Grant RA, Morales-Nebreda L, Markov NS, et al. Circuits between infected macrophages and T cells in SARS-CoV-2 pneumonia. Nature. 2021;590(7847):635–641. doi: 10.1038/s41586-020-03148-w
   PubMed Web of Science ®Google Scholar
• Amin S, Rahim F, Bahadur S, et al. The effect of tocilizumab on inflammatory markers in survivors and non-survivors of severe COVID-19. J Coll Physicians Surg Pak. 2021;31(1):S7–S10.
   PubMed Web of Science ®Google Scholar
• Berlin DA, Gulick RM, Martinez FJ. Severe Covid-19. N Engl J Med. 2020;383(25):2451–2460. doi: 10.1056/NEJMcp2009575
   PubMed Web of Science ®Google Scholar
• Zhou YW, Xie Y, Tang LS, et al. Therapeutic targets and interventional strategies in COVID-19: mechanisms and clinical studies. Sig Transduct Target Ther. 2021;6(1):317. doi: 10.1038/s41392-021-00733-x
   PubMed Web of Science ®Google Scholar
• Elbadawy HM, Khattab A, El-Agamy DS, et al. IL-6 at the center of cytokine storm: Circulating inflammation mediators as biomarkers in hospitalized COVID-19 patients. Clinical Laboratory Analysis. 2023;37(7):e24881. doi: 10.1002/jcla.24881
   PubMed Web of Science ®Google Scholar
• Chen YW, Liao HT. Tocilizumab alleviates cytokine storm with acute respiratory distress syndrome in severe SARS-CoV-2 infection in Taiwan. Intern Med J. 2021;51(9):1543–1544. doi: 10.1111/imj.15335
   PubMed Web of Science ®Google Scholar
• Kalil AC, Stebbing J. Baricitinib: the first immunomodulatory treatment to reduce COVID-19 mortality in a placebo-controlled trial. Lancet Respir Med. 2021;9(12):1349–1351. doi: 10.1016/S2213-2600(21)00358-1
   PubMed Web of Science ®Google Scholar
• Kawazoe M, Kihara M, Nanki T. Antirheumatic drugs against COVID-19 from the perspective of Rheumatologists. Pharmaceuticals (Basel). 2021;14(12):1256. doi: 10.3390/ph14121256
   PubMedGoogle Scholar
• O’Halloran J, Kedar E, Anstrom KJ, et al. Infliximab for treatment of adults hospitalized with moderate or severe Covid-19. medRxiv. 2022;36:1114–1121.
   Google Scholar
• Ko ER, Anstrom KJ, Panettieri RA, et al. Abatacept for treatment of adults hospitalized with moderate or severe Covid-19. medRxiv. 2022;51:3328–3336.
   Google Scholar
• McCarthy MW. Optimizing the use of Paxlovid in clinical practice. Drugs Today (Barc). 2022;58(11):539–546. doi: 10.1358/dot.2022.58.11.3461265
   PubMed Web of Science ®Google Scholar
• Brust KB, Papineni V, Columbus C, et al. COVID-19-from emerging global threat to ongoing pandemic crisis. Proc (Bayl Univ Med Cent). 2022;35(4):468–475. doi: 10.1080/08998280.2022.2068940
   PubMedGoogle Scholar